Titelbild von SandozSandoz
Sandoz

Sandoz

Arzneimittelherstellung

Basel, BS 1.130.587 Follower:innen

Info

Sandoz is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion. Read our community engagement guidelines: http://bit.ly/4ofoggc

Website
https://www.sandoz.com
Branche
Arzneimittelherstellung
Größe
10.001+ Beschäftigte
Hauptsitz
Basel, BS
Art
Kapitalgesellschaft (AG, GmbH, UG etc.)
Spezialgebiete
Generics, Biosimilars und Over the counter medicines

Orte

Beschäftigte von Sandoz

Updates

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    A strong follow‑up from Chief Transformation & Growth Officer Simon Goeller on the strategic importance of Europe’s last fully integrated penicillin production site in Kundl, Austria. In his second interview on this topic, he reinforces why preserving this end‑to‑end manufacturing capability is vital for Europe’s security of supply and long‑term resilience - capacity that cannot be quickly rebuilt once lost. He also raises a central question: How should Europe balance security of supply and sustainability in antibiotics?

    Europe’s last strategic penicillin asset: Kundl Europe today has only one fully integrated penicillin production site remaining — in Kundl, Austria — covering fermentation, active ingredient production and finished dosage forms under one roof.   Across NATO and NATO Partnership for Peace territory, this is the last large-scale end-to-end facility of its kind. That makes it more than an industrial site. It is a strategic capability. Once such infrastructure is lost, rebuilding it takes years. In a crisis, years are not available.   In this interview, I share why preserving existing manufacturing capacity in Europe is essential for long-term resilience. What do you think? How should Europe balance security of supply and sustainability in antibiotics? I’d love your perspective in the comments.

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    A powerful message from our Chief Transformation & Growth Officer Simon Goeller on why antibiotics must be recognized as critical infrastructure. They underpin modern medicine, protect societal stability, strengthen defense readiness, and support resilience planning Raising awareness is key - and this conversation couldn’t be more urgent 🚨.

    Antibiotics are critical infrastructure. Modern medicine depends on them. Surgeries, infection treatment, intensive care and routine procedures all rely on effective antibiotics. Without them, life expectancy would decline significantly and healthcare systems would face severe disruption.   Antibiotics are not just healthcare commodities. They are foundational to societal stability and defense readiness alike. If we define energy grids, transport systems and digital networks as critical infrastructure, we must apply the same logic to essential medicines.   In this interview, I explain why antibiotics must be treated as system-relevant infrastructure — not only as part of healthcare policy, but as part of resilience planning. The purpose is simple: raise awareness. So, if you agree, please repost. If you disagree or have questions, feel free to comment. Thanks!

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    Today, we announce a new global unit to accelerate growth in our biosimilar medicines business while further strengthening our high volume generics portfolio. Our goal is clear: sharpen focus, boost biosimilars growth and secure a long term competitive edge. The new Sandoz biosimilar development, manufacturing and supply unit will be operative as of April 1 and led by industry veteran Armin Metzger, who joins us from Ferring Pharmaceuticals. Mr. Metzger says: ‘I’m honored and excited to be joining the global pioneer and leader in biosimilar medicines at a critical moment in the history of the industry. There’s an unprecedented opportunity over the next decade to drive patient access to affordable biologics and Sandoz is uniquely positioned to seize it.” 📰For more details, read the full media release: https://lnkd.in/dazHXnYw

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    Equal opportunity does not happen by default. It happens when we actively create it through rights that are protected, justice that is upheld and actions that move us forward. That is also the message behind this year’s UN theme for International Women’s Day: “𝐑𝐢𝐠𝐡𝐭𝐬. 𝐉𝐮𝐬𝐭𝐢𝐜𝐞. 𝐀𝐜𝐭𝐢𝐨𝐧. 𝐅𝐨𝐫 𝐀𝐋𝐋 𝐖𝐨𝐦𝐞𝐧 𝐚𝐧𝐝 𝐆𝐢𝐫𝐥𝐬.” In his post, our CEO Richard Saynor reflects on why creating fair and inclusive environments matters: for individuals, stronger teams and better outcomes. At Sandoz, we believe diverse perspectives and equal access to opportunity strengthen leadership and the impact we can have for patients. #InternationalWomensDay #ForAllWomenAndGirls #SandozLife

    There is an often-cited finding from a Hewlett-Packard internal report that highlights how men will apply for a job when they meet only 60% of qualifications, whilst women often wait until they feel 100% ready. This “readiness gap” isn’t simply about a lack of relevant skills but also a reflection of the biases that dictate who feels they are “allowed” to lead. When I was living and working in Asia, I led a business with a predominantly female leadership team. To be clear: this wasn’t by design and neither was it an “initiative”. It was simply the result of hiring the best talent for the job. That experience has stayed with me because it proved a simple truth that having a female-led team didn’t make the business any different. In fact, we excelled. This year’s official UN Women theme for International Women's Day is “Rights. Justice. Action. For ALL Women and Girls”. To me, this is an important reminder that creating equality is not about asking women to give more or prove more. It is about ensuring fairness, consistency and opportunity. When women are afforded the same license to be “60% ready” that we afford men and when we look beyond our own biases, we don’t just take a step toward a more equitable society. We also open ourselves up to more possibilities. New potential that was previously sidelined, fresh perspectives that drive innovation, and ultimately, stronger outcomes because we are drawing from the widest possible talent pool. This International Women's Day, and frankly every day before and after, let’s recognize women not as a separate category. The bar for excellence is the same for all, and women clear it every day. #IWD2026

    • Kein Alt-Text für dieses Bild vorhanden
  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    This year, we honor the history that shaped us and the Purpose that drives us forward. 💙🚀 Tracing its roots back to 1886 in Basel, Switzerland, Sandoz is a global generics and biosimilars leader, reaching over 1 billion patients annually. With 140 years of heritage and just a little over 2 years as a listed company, reinvention is in our DNA. 🧬 Our story is long and still being written. Stay tuned. Visit our Sandoz anniversary page to learn more: https://lnkd.in/emYCPmrB

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    Following the publication of the Sandoz 2025 Annual Report, we’re sharing a highlights video today that brings the year’s most important results into focus. 🎥📊 The results showcased in the report demonstrate how we accelerated growth across our biosimilars portfolio, strengthened our base generics business and advanced our Purpose: pioneering access for patients. As our CFO, Remco Steenbergen, says: “Our hard work since the spin has led to strong results to date, which positions us well to reach our mid-term outlook for 2028, which is unchanged. We have strong momentum, supported by numerous launches across key markets, and there is clear visibility on the drivers of our margin expansion. “We delivered strong underlying net‑sales growth of 6% in 2025, driven by another year of double‑digit expansion in biosimilars. Importantly, this momentum was broad‑based, with all regions contributing, underscoring the resilience and diversification of our business. Core EBITDA increased by 14%, with the margin reaching 21.7%, and management free cash flow increased to 1.5 billion US dollars. “This is a strong win-win for Sandoz, for our investors and for the patients we ultimately serve.” ▶️ Watch the highlights video below   🔗 Dive into our online Annual Report https://lnkd.in/d3CnRR9H

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    Today, Sandoz announced its full-year financial results for 2025, with strong year-on-year net sales growth of 5% at constant currencies and an underlying growth rate of 6% (comparative growth rate, CGR). Growth was driven by biosimilars (+13%, +18% CGR), while the base generics business grew by 2%. The core EBITDA margin grew by 160 basis points to 21.7%. We also announced 2026 guidance of mid-to-high single-digit net sales growth and a core EBITDA margin expansion of around 100 basis points. For further details, read the media release 📰https://lnkd.in/d6gsX3iD and watch the video of our CEO, Richard Saynor. 👇 What comes next? In 2026, Sandoz celebrates three historic milestones:  🏢140 years of Sandoz heritage  💊80 years of antibiotic expertise 🧪20 years launch of the world’s first biosimilar Follow along as we share anniversary moments throughout the year and join us in telling the stories that will shape what comes next.

  • Unternehmensseite für Sandoz anzeigen

    1.130.587 Follower:innen

    Strengthening our clean energy approach in Europe ☀️ Sandoz is joining two new multi-buyer virtual Power Purchase Agreements (vPPAs) in Europe with nine strategic suppliers, bundling demand across healthcare to help bring new clean energy projects online through the Energize program run by Schneider Electric. These agreements build on the vPPA we signed in 2025, expected to cover nearly 90% of current electricity demand across our European operations, and further support decarbonization across the value chain. Lynn De Proft our Chief Procurement Officer, noted: “This step reflects our commitment to operate responsibly and promote renewable electricity. By joining the Energize cohorts, we aim to contribute to a more sustainable healthcare system.” 📰Read more in our company news: https://lnkd.in/daaPNQEa Gerresheimer BD

    • Kein Alt-Text für dieses Bild vorhanden

Verbundene Seiten

Ähnliche Seiten

Finanzierung

Sandoz Insgesamt 2 Finanzierungsrunden

Letzte Runde

Fremdkapital nach Börsengang

667.327.321,00 $

Weitere Informationen auf Crunchbase